R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
News UCB cuts $1.15bn deal to buy epilepsy biotech Neurona UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
News MoonLake secures $500m for lead drug, plus other financings MoonLake secures $500m in financing for lead inflammatory disease drug sonelokimab while AIRNA, Atsena, and Neurona complete $100m+ private rounds.
News UK MHRA authorises orforglipron private prescription Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.